Beyond the Blood Draw: Making Liquid Biopsy More Accurate, One Mutation at a Time
Matthew Oberley, MD, PhD
As liquid biopsy becomes a standard tool in oncology, distinguishing tumor signals from clonal hematopoiesis is essential for accurate results
Matthew Oberley, MD, PhD
Dr. Matthew J. Oberley is senior vice president, chief clinical officer, and pathologist-in-chief at Caris Life Sciences. Since joining Caris in 2019, he has led the pathology and molecular genetics group of 40+ specialists and spearheaded deployment of a high-capacity digital pathology system generating over a million slide scans annually. A board-certified pathologist, he has authored more than 150 publications and previously served as director of hematopathology at Children’s Hospital Los Angeles.